Comments to U.S. Trade Representative: China Share page: Docket Number: USTR-2018-0005 CHPA is pleased to provide comments on behalf of our members in response to the notice regarding the “acts, policies, and practices of China determined to be unreasonable or discriminatory and to burden or restrict U.S. commerce.” Download Document Issues: OTC Medicines Related Posts Press Releases and Statements House Leaders Prioritize OMUFA Renewal, CHPA Welcomes Progress Apr 1, 2025 Press Releases and Statements CHPA Statement on Senate Confirmation of Dr. Makary as FDA Commissioner Mar 25, 2025 Press Releases and Statements CHPA Applauds New Mississippi Law to Prevent Unlawful Purchases of PSE-Containing Medicines Mar 21, 2025